Ignite Creation Date:
2024-05-05 @ 12:05 PM
Last Modification Date:
2024-10-26 @ 9:20 AM
Study NCT ID:
NCT00235391
Status:
COMPLETED
Last Update Posted:
2011-06-07
First Post:
2005-10-06
Brief Title:
Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Myelofibrosis |
| Thalassemia |
| Sickle Cell Disease |
| Diamond Blackfan Anemia |
Keywords:
| Name | View |
|---|---|
| ICL670A | View |
| Deferasirox | View |
| Congenital Anemias | View |
| Anemias | View |
| Red Blood Cell Disorders | View |
| Chronic Iron Overload | View |
| Transfusional Iron Overload | View |
| Iron Chelators | View |
| Oral Iron Chelators | View |
| Thalassemia | View |
| Sickle Cell Disease | View |
| Diamond Blackfan Anemia | View |
| Myelofibrosis | View |